{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:39:04Z","timestamp":1792597144860,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajt.2026.05.729","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:18:13Z","timestamp":1779376693000},"page":"2383-2393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-4589","authenticated-orcid":false,"given":"David J.","family":"Taber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Culpepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Overstreet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Vaishnav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Aurora","family":"Posadas Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Hanish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.ajt.2026.05.729_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.12002","article-title":"Overview: cytomegalovirus and the herpesviruses in transplantation","volume":"13","author":"Fishman","year":"2013","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2026.05.729_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: a systematic literature review of real-world evidence","volume":"23","author":"Raval","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ajt.2026.05.729_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2020.100587","article-title":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: a systematic review of randomized controlled trials","volume":"35","author":"Raval","year":"2020","journal-title":"Transplant Rev (Orlando)"},{"issue":"5","key":"10.1016\/j.ajt.2026.05.729_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14318","article-title":"Evolving trends in immunosuppression use and cytomegalovirus infection risk over the past decade in kidney transplantation","volume":"26","author":"Soliman","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.ajt.2026.05.729_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2026.05.729_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/15269248211024614","article-title":"Predictors and complications of post kidney transplant leukopenia","volume":"31","author":"Vinson","year":"2021","journal-title":"Prog Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13617","article-title":"Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation","volume":"23","author":"Jorgenson","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.ajt.2026.05.729_bib9","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.transproceed.2019.04.078","article-title":"Efficacy and safety of ultra-low-dose valganciclovir chemoprophylaxis for cytomegalovirus infection in high-risk kidney transplantation patients","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling","year":"2018","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1526924818765798","article-title":"Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophylaxis","volume":"28","author":"Liang","year":"2018","journal-title":"Prog Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1526924817731880","article-title":"Evaluation of filgrastim therapy in kidney transplant recipients","volume":"27","author":"Poon","year":"2017","journal-title":"Prog Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2026.05.729_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ajt.2026.05.729_bib14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajt.2026.05.729_bib15","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2026.05.729_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1473-3099(11)70033-0","article-title":"Why did maribavir fail in stem-cell transplants?","volume":"11","author":"Snydman","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.ajt.2026.05.729_bib20","article-title":"A randomized controlled trial comparing the tolerability and efficacy of maribavir vs. valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients: study protocol","volume":"17","author":"Culpepper","year":"2025","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ajt.2026.05.729_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13541","article-title":"Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation","volume":"33","author":"Hamel","year":"2019","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib23","doi-asserted-by":"crossref","DOI":"10.5500\/wjt.v15.i2.102671","article-title":"Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir","volume":"15","author":"Beyer","year":"2025","journal-title":"World J Transplant"},{"issue":"11S","key":"10.1016\/j.ajt.2026.05.729_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.20223311S1551c","article-title":"Healthcare utilization and costs associated with neutropenia in kidney transplant recipients receiving valganciclovir prophylaxis: an administrative claims database study: FR-PO829","volume":"33","author":"Turzhitsky","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2026.05.729_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs. valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ajt.2026.05.729_bib27","series-title":"Prescribing Information","year":"2021"},{"issue":"4","key":"10.1016\/j.ajt.2026.05.729_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13869","article-title":"Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients","volume":"24","author":"Sabatino","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ajt.2026.05.729_bib29","series-title":"Prescribing information. Merck Sharp & Dohme","year":"2017"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ajt.2026.05.729_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ajt.2026.05.729_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001659","article-title":"Mycophenolate dose reduction in tacrolimus-based regimens and long-term kidney transplant outcomes in Australia and New Zealand","volume":"10","author":"Lee","year":"2024","journal-title":"Transplant Direct"},{"issue":"9","key":"10.1016\/j.ajt.2026.05.729_bib33","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ajt.2026.05.729_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/tri.12133","article-title":"Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome","volume":"26","author":"Vanhove","year":"2013","journal-title":"Transpl Int"},{"issue":"12","key":"10.1016\/j.ajt.2026.05.729_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15142","article-title":"Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: letermovir reverses leukopenia and avoids mycophenolate dose reduction","volume":"37","author":"Jorgenson","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ajt.2026.05.729_bib36","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.2147\/DDDT.S265644","article-title":"Current perspectives on letermovir and maribavir for the management of cytomegalovirus infection in solid organ transplant recipients","volume":"18","author":"Razonable","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajt.2026.05.729_bib37","article-title":"Micromedex Red Book","year":"2023","journal-title":"Merative"},{"issue":"2","key":"10.1016\/j.ajt.2026.05.729_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antiviral Res"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526009962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526009962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:42:00Z","timestamp":1792593720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526009962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1600613526009962"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2026.05.729","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2026.05.729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}